Press Releases

Press Releases

Date Title
06/24/20 Vaxart, Inc. Set to Join Russell 3000® Index
SOUTH SAN FRANCISCO, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell
06/23/20 Vaxart, Inc. to Present at the H.C. Wainwright Virtual Fireside Chat Series
Live Webcast on Thursday June 25th at 10:25 am ET SOUTH SAN FRANCISCO, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced
06/15/20 Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
Andrei Floroiu Appointed Chief Executive Officer Wouter Latour , MD, to Continue as Chairman of the Board SOUTH SAN FRANCISCO, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NasdaqCM: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant
06/03/20 Vaxart to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.  (“ Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that
05/20/20 Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated SOUTH SAN FRANCISCO, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“ Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant
05/12/20 Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
Lead Vaccine Candidates for COVID-19 are Highly Immunogenic in Preclinical Testing COVID-19 Phase 1 Clinical Study Planned for 2H20 SOUTH SAN FRANCISCO, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral
04/30/20 Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Robust Boosting of Immune Responses Observed after Second Dose SOUTH SAN FRANCISCO, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that
04/28/20 Vaxart Announces Corporate Update for First Quarter 2020
Preparations for the Manufacturing of GMP Vaccine at Emergent BioSolutions Ongoing Vaxart is Participating in Maxim’s Infectious Disease Virtual Conference on May 5, 2020 SOUTH SAN FRANCISCO, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company
04/21/20 Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose SOUTH SAN FRANCISCO, Calif. , April 21, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
03/31/20 Vaxart Provides Update on its Oral COVID-19 Vaccine Program
Five COVID-19 Vaccine Candidates in Preclinical Testing Development Services to Enable Manufacture of cGMP Vaccine at Emergent BioSolutions have Started SOUTH SAN FRANCISCO, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant